The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.
Mehmet Emin BuyukbayramZekeriya HannariciYakup DuzkopruAykut TurhanAlperen Akansel CaglarPınar Coban EsdurMehmet BiliciSalim Basol TekinDoğan YazılıtaşPublished in: Breast cancer (Dove Medical Press) (2024)
In patients with metastatic hormone-positive breast cancer using CDK4/6i, low CLR and low Ki67 were correlated with longer PFS duration.